Pfizer PFE announces its next round of earnings this Tuesday, January 28. Here is Benzinga's everything-that-matters guide for the Q4 earnings announcement.
Earnings and Revenue
Pfizer EPS is expected to be around 57 cents, according to sell-side analysts. Sales will likely be near $12.61 billion.
Pfizer earnings in the same period a year ago was 64 cents. Quarterly sales came in at $13.98 billion. If the company were to report inline earnings when it publishes results Tuesday, earnings would be down 10.94%. Sales would have fallen 9.77% from the same quarter last year. Here's how the company's reported EPS has stacked up against analyst estimates in the past:
| Quarter | Q3 2019 | Q2 2019 | Q1 2019 | Q4 2018 |
| EPS Estimate | 0.620 | 0.750 | 0.75 | 0.64 |
| EPS Actual | 0.750 | 0.800 | 0.850 | 0.64 |
Stock Performance
Over the last 52-week period, shares are down 2.76%. Given that these returns are generally negative, long-term shareholders are probably a little upset going into this earnings release. Over the past 90 days, analysts have adjusted their estimates lower for EPS and revenues. The most common rating from analysts on Pfizer stock is a Neutral. The strength of this rating has maintained conviction over the past three months.
Conference Call
Pfizer is scheduled to hold a conference call at 10:00 a.m. ET and it can be accessed here: https://www.webcaster4.com/Webcast/Page/748/32428
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
